10x Genomics, Inc. TXG Accounts Receivable
Accounts Receivable at other companies
Other financials
Where this comes from
Reported directly by 10x Genomics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccountsReceivableNetCurrent.
The official record: 10x Genomics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about 10x Genomics, Inc.'s accounts receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is 10x Genomics, Inc.'s accounts receivable?
- 10x Genomics, Inc. (TXG) reported accounts receivable of $39.03M in Q1 2026.
- How has 10x Genomics, Inc.'s accounts receivable changed year-over-year?
- 10x Genomics, Inc.'s accounts receivable decreased by 25.7% year-over-year, from $52.55M to $39.03M.
- What is the long-term trend for 10x Genomics, Inc.'s accounts receivable?
- Over 4 years (2021 to 2025), 10x Genomics, Inc.'s accounts receivable has grown at a -8.9% compound annual growth rate (CAGR), from $280.77M to $193.32M.
- What does accounts receivable mean?
- Amounts owed by customers for goods delivered or services performed, net of allowances for doubtful accounts. A key working capital component.